Compare BTCS & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BTCS | TTRX |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.7M | 116.0M |
| IPO Year | N/A | N/A |
| Metric | BTCS | TTRX |
|---|---|---|
| Price | $1.65 | $3.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $7.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 977.8K | 31.5K |
| Earning Date | 03-19-2026 | 05-13-2026 |
| Dividend Yield | ★ 3.01% | N/A |
| EPS Growth | ★ 644.42 | N/A |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $11,724,983.00 | N/A |
| Revenue This Year | $248.05 | N/A |
| Revenue Next Year | $41.01 | N/A |
| P/E Ratio | $0.94 | ★ N/A |
| Revenue Growth | ★ 464.28 | N/A |
| 52 Week Low | $1.25 | $2.57 |
| 52 Week High | $8.49 | $26.50 |
| Indicator | BTCS | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 29.09 | 35.76 |
| Support Level | $1.48 | $3.55 |
| Resistance Level | $1.85 | $3.80 |
| Average True Range (ATR) | 0.20 | 0.26 |
| MACD | -0.05 | -0.11 |
| Stochastic Oscillator | 12.99 | 0.00 |
BTCS Inc. ("BTCS" or the "Company"), short for Blockchain Technology Consensus Solutions, is a U.S.-based Ethereum-first blockchain technology company committed to driving scalable revenue and ETH accumulation through its hallmark strategy, the DeFi/TradFi Accretion Flywheel, an integrated approach to capital formation and blockchain infrastructure. By combining decentralized finance ("DeFi") and traditional finance ("TradFi") mechanisms with its blockchain infrastructure operations, comprising NodeOps (staking) and Builder+ (block building), BTCS offers one of the most sophisticated opportunities for leveraged ETH exposure, driven by scalable revenue generation and a yield-focused ETH accumulation strategy. Discover how BTCS offers operational and financial leveraged exposure to Ethereum through the public markets at www.btcs.com.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.